Under this deal, Philochem will grant RayzeBio exclusive worldwide rights to develop, manufacture, and market OncoACP3, a ...

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...

The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate ...

OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in ...

BMS kickstarted its radiopharma drive last year when it completed a $4.1 billion acquisition of San Diego-based RayzeBio, ...

US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...

In accordance with the agreement, Philochem will get $350 million up front and could get up to $1 billion in milestone ...

Philochem to license worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer to RayzeBio: Otelfingen, Switzerland Thur ...

Bristol MyersBMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis ...

Switzerland-based Philochem and Bristol Myers Squibb (NYSE: BMY) radiopharma subsidiary RayzeBio have announced a definitive agreement under which Philochem will license the exclusive worldwide rights ...

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...